Actavis completes $71bn acquisition of Allergan
Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.
In a statement today (March 17), Actavis said that the deal creates one of the world’s ten largest pharma companies by sales revenue.
Allergan makes products including Botox and Juvéderm.
Brent Saunders, chief executive of Actavis, said he believes the new company (known as Actavis) has many first-to-file generic opportunities in the US and that it now has more than 1,000 marketing authorisations worldwide.
Saunders added: “Anchored by world-renowned brand franchises, a leading global generics business, a premier pharma development pipeline and an experienced management team committed to maintaining highly efficient operations across the organisation, we are creating an unrivalled foundation for long-term growth.”
The European Commission confirmed the transaction’s closure yesterday (March 16). Details of the acquisition were first announced in November last year.
